Bionano Genomics announced that Al Luderer, Ph.D., chairman of the company’s Board of Directors, has been appointed interim president and chief executive officer effective May 5, 2026.
Luderer will continue serving as chairman of the board while director Chris Twomey assumes the role of Lead Independent Director. He succeeds Erik Holmlin, Ph.D., who will remain with the company in an advisory capacity. Bionano said it expects the leadership transition to occur without business disruption.
Luderer has served on Bionano’s Board of Directors since November 2011 and has been chairman since June 2024. The company said he brings more than 30 years of biotechnology industry experience focused on technology, commercialization, and business development. His prior leadership roles include serving as CEO of Indi Molecular, president and CEO of BioTrove, CEO of Light Sciences, and president and COO of bioMérieux.
Bionano is a provider of genome analysis solutions focused on optical genome mapping technologies, diagnostic services, genome analysis software, and nucleic acid extraction and purification technologies. The company said its products are designed to support researchers and clinicians in genomic analysis across basic, translational, and clinical research applications.
The company also operates Bionano Laboratories, which provides optical genome mapping-based diagnostic testing services.
KEY QUOTES:
“I am honored to step into this role and deeply committed to Bionano’s mission and the long-term opportunity we are pursuing. Having worked closely with this team as Chairman, I have a clear view of both the strengths of this organization and the work ahead. I look forward to working alongside our talented employees, partners, and shareholders to maintain momentum and position Bionano well for its next chapter of growth, and look forward to working with the Board on identifying our next CEO. I also want to thank Erik for his contributions and dedication to Bionano.”
Al Luderer, Interim President And Chief Executive Officer, Bionano Genomics
“Al brings an extraordinary combination of deep industry expertise and intimate knowledge of Bionano, having been a trusted member of our Board for more than a decade and serving as Chairman since 2024. His three decades of experience leading biotechnology and life sciences companies – from early-stage technology development through commercialization – make him exceptionally well-suited to lead Bionano through this transition. The Board has full confidence in Al’s ability to provide strong and steady leadership as we conduct a thorough search for our next permanent Chief Executive Officer.”
Chris Twomey, Lead Independent Director, Bionano Genomics
